Latest Regulatory Approval News

Lynas Rare Earths is set to boost its Heavy Rare Earths production with a new separation plant in Malaysia, aiming to meet rising global demand outside China. The A$180 million project will leverage Lynas’ Mt Weld deposit and local resources to supply critical materials for advanced manufacturing.

Elevra Lithium has completed a transformative merger and maintained robust production at its North American Lithium operation, while unveiling a compelling expansion plan that could boost output by 55% and slash costs.

QPM Energy has made significant strides in advancing its 112MW Isaac Power Station, securing major financing and operational milestones that position it well for mid-2027 commissioning.

VRX Silica Limited has entered a conditional contract to acquire the Arramall farm site adjacent to its Arrowsmith North project, aiming to reduce capital and operating costs while shrinking its environmental footprint.

Suzerain Investments Holdings Limited has initiated an off-market takeover bid for all remaining shares of Entertainment Rewards Ltd (EAT) at $0.022 per share, a substantial premium over recent trading prices. The offer comes with unanimous support from EAT's Independent Board Committee, subject to regulatory approvals and an independent expert's fairness opinion.

Triangle Energy (Global) Limited has amended its quarterly cash flow report to correct key figures while advancing new permits in the Philippines and progressing the transition of its Cliff Head Oil Field to a carbon capture and storage project.

Arafura Rare Earths has made decisive strides in funding its Nolans Project, securing up to US$400 million in conditional and indicative investments from Australian and US government-linked financiers, alongside a strong equity raise.

Black Dragon Gold’s latest quarterly report highlights strong local backing for its Salave gold project in Spain, alongside a key director resignation and a stable cash position of CAD$882,000.

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Diatreme Resources reported progress on its Northern Silica Project with key regulatory approvals and metallurgical successes, while agreeing to sell its Clermont Copper/Gold Project to Moonlight Resources, retaining a significant stake.

Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.